BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37216402)

  • 1. NF1 Gene Inactivation Acts as Tumor Driver in RET/RAS Negative Medullary Thyroid Carcinomas.
    Ciampi R; Ramone T; Romei C; Casalini R; Matrone A; Prete A; Gambale C; Minardi SP; Caparezza G; Pierotti MA; Torregrossa L; Ugolini C; Materazzi G; Elisei R
    Eur J Endocrinol; 2023 May; ():. PubMed ID: 37216402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Not Only
    Castroneves LA; Mangone FRR; Lerario AM; da Cunha Mercante AM; Batista RL; Barros LRC; Ferreira CV; Farias EC; Vanderlei FAB; Maia AL; Nagai MA; Jorge AAL; Hoff AO
    J Endocr Soc; 2024 Apr; 8(6):bvae059. PubMed ID: 38655100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.
    Moura MM; Cavaco BM; Pinto AE; Leite V
    J Clin Endocrinol Metab; 2011 May; 96(5):E863-8. PubMed ID: 21325462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon.
    Boichard A; Croux L; Al Ghuzlan A; Broutin S; Dupuy C; Leboulleux S; Schlumberger M; Bidart JM; Lacroix L
    J Clin Endocrinol Metab; 2012 Oct; 97(10):E2031-5. PubMed ID: 22865907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retroposed copies of RET gene: a somatically acquired event in medullary thyroid carcinoma.
    Bim LV; Navarro FCP; Valente FOF; Lima-Junior JV; Delcelo R; Dias-da-Silva MR; Maciel RMB; Galante PAF; Cerutti JM
    BMC Med Genomics; 2019 Jul; 12(1):104. PubMed ID: 31288802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland.
    Ciampi R; Romei C; Pieruzzi L; Tacito A; Molinaro E; Agate L; Bottici V; Casella F; Ugolini C; Materazzi G; Basolo F; Elisei R
    J Endocrinol Invest; 2017 Jan; 40(1):55-62. PubMed ID: 27535135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prevalence of somatic RAS mutations in medullary thyroid cancer - a Polish population study.
    Oczko-Wojciechowska M; Pfeifer A; Rusinek D; Pawlaczek A; Zebracka-Gala J; Kowalska M; Kowal M; Swierniak M; Krajewska J; Gawlik T; Chmielik E; Czarniecka A; Szpak-Ulczok S; Jarząb B
    Endokrynol Pol; 2015; 66(2):121-5. PubMed ID: 25931041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series.
    Ciampi R; Mian C; Fugazzola L; Cosci B; Romei C; Barollo S; Cirello V; Bottici V; Marconcini G; Rosa PM; Borrello MG; Basolo F; Ugolini C; Materazzi G; Pinchera A; Elisei R
    Thyroid; 2013 Jan; 23(1):50-7. PubMed ID: 23240926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatic VHL gene alterations in MEN2-associated medullary thyroid carcinoma.
    Koch CA; Brouwers FM; Vortmeyer AO; Tannapfel A; Libutti SK; Zhuang Z; Pacak K; Neumann HP; Paschke R
    BMC Cancer; 2006 May; 6():131. PubMed ID: 16707008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel point mutations and allele loss at the RET locus in sporadic medullary thyroid carcinomas.
    Uchino S; Noguchi S; Adachi M; Sato M; Yamashita H; Watanabe S; Murakami T; Toda M; Murakami N; Yamashita H
    Jpn J Cancer Res; 1998 Apr; 89(4):411-8. PubMed ID: 9617347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-throughput mutation profiling improves diagnostic stratification of sporadic medullary thyroid carcinomas.
    Simbolo M; Mian C; Barollo S; Fassan M; Mafficini A; Neves D; Scardoni M; Pennelli G; Rugge M; Pelizzo MR; Cavedon E; Fugazzola L; Scarpa A
    Virchows Arch; 2014 Jul; 465(1):73-8. PubMed ID: 24828033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RAS proto-oncogene in medullary thyroid carcinoma.
    Moura MM; Cavaco BM; Leite V
    Endocr Relat Cancer; 2015 Oct; 22(5):R235-52. PubMed ID: 26285815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RET Copy Number Alteration in Medullary Thyroid Cancer Is a Rare Event Correlated with RET Somatic Mutations and High Allelic Frequency.
    Ramone T; Mulè C; Ciampi R; Bottici V; Cappagli V; Prete A; Matrone A; Piaggi P; Torregrossa L; Basolo F; Elisei R; Romei C
    Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33383911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomics and Epigenomics of Medullary Thyroid Carcinoma: From Sporadic Disease to Familial Manifestations.
    Barletta JA; Nosé V; Sadow PM
    Endocr Pathol; 2021 Mar; 32(1):35-43. PubMed ID: 33492588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS.
    Agrawal N; Jiao Y; Sausen M; Leary R; Bettegowda C; Roberts NJ; Bhan S; Ho AS; Khan Z; Bishop J; Westra WH; Wood LD; Hruban RH; Tufano RP; Robinson B; Dralle H; Toledo SP; Toledo RA; Morris LG; Ghossein RA; Fagin JA; Chan TA; Velculescu VE; Vogelstein B; Kinzler KW; Papadopoulos N; Nelkin BD; Ball DW
    J Clin Endocrinol Metab; 2013 Feb; 98(2):E364-9. PubMed ID: 23264394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with double
    Romei C; Casella F; Tacito A; Bottici V; Valerio L; Viola D; Cappagli V; Matrone A; Ciampi R; Piaggi P; Ugolini C; Torregrossa L; Basolo F; Materazzi G; Vitti P; Elisei R
    J Med Genet; 2016 Nov; 53(11):729-734. PubMed ID: 27468888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas.
    Komminoth P; Kunz EK; Matias-Guiu X; Hiort O; Christiansen G; Colomer A; Roth J; Heitz PU
    Cancer; 1995 Aug; 76(3):479-89. PubMed ID: 8625130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient affected by neurofibromatosis type 1 and thyroid C-cell hyperplasia harboring pathogenic germ-line mutations in both NF1 and RET genes.
    Ercolino T; Lai R; Giachè V; Melchionda S; Carella M; Delitala A; Mannelli M; Fanciulli G
    Gene; 2014 Feb; 536(2):332-5. PubMed ID: 24361808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germline sequence variant S836S in the RET proto-oncogene is associated with low level predisposition to sporadic medullary thyroid carcinoma in the Spanish population.
    Ruiz A; Antiñolo G; Fernández RM; Eng C; Marcos I; Borrego S
    Clin Endocrinol (Oxf); 2001 Sep; 55(3):399-402. PubMed ID: 11589684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in the cysteine-rich region of the RET proto-oncogene in patients diagnosed as having sporadic medullary thyroid carcinoma.
    Kimura T; Yoshimoto K; Yokogoshi Y; Saito S
    Endocr J; 1995 Aug; 42(4):517-25. PubMed ID: 8556059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.